Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

TARRYTOWN, N.Y., Dec. 1, 2018 /PRNewswire/ -- 100% overall and 80% complete response rate in 10 patients with relapsed or refractory follicular lymphoma treated with 5 mg or more of REGN1979 Plan to initiate in 2019 a potentially registrational Phase 2 trial in relapsed or refractory...

from PR Newswire: https://ift.tt/2AEhJ8x